STING1 and breast carcinoma: Other studies have also found that the cGAS-STING signal pathway could regulate CD8+ T cells differentiation to produce anti-tumor responses, including hepatocellular carcinoma, breast cancer, melanoma, colon cancer, and lung cancer (31, 47–52).